SEER
TECX
IVVD
CYCN
ALEC

Terrance McGuire

Known title: DirectorCIK: 0001117003

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 28, 2026

Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.

this person other insiders at SEER

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.

this person other insiders at TECX

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 27, 2026

IVVD noted among health-care stocks moving on Monday. Invivyd (IVVD) was listed among twelve health-care stocks that showed price movement in Monday’s pre-market and intraday sessions, according to Benzinga. The mention reflects short-term trading activity but does not indicate a specific catalyst for the company.

this person other insiders at IVVD
this person other insiders at CYCN

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 27, 2026

Alector (ALEC) sees purchases by NVIDIA and Merck. Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.

this person other insiders at ALEC

Transaction History

SEER▲ Buy$0
SEER▼ Sell—
SEER▲ Buy$0
TECX▼ Sell$8.6M
IVVD▼ Sell$46K
IVVD▼ Sell$42K
IVVD▼ Sell$44K
IVVD▼ Sell$46K
IVVD▼ Sell$35K
IVVD▼ Sell$34K
IVVD▼ Sell$51K
IVVD▼ Sell$66K
IVVD▼ Sell$35K
IVVD▼ Sell$47K
IVVD▼ Sell$31K
IVVD▼ Sell$73K
IVVD▼ Sell$95K
IVVD▼ Sell$103K
IVVD▼ Sell$92K
TECX▲ Buy—
TECX▲ Buy—
TECX▲ Buy—
SEER▲ Buy$0
IVVD▼ Sell$187K
CYCN▲ Buy$0
ALEC▼ Sell$3.0M
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
CYCN▼ Sell$27
SEER▲ Buy$0
ALEC▲ Buy$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▲ Buy$0
SEER▲ Buy$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
ALEC▼ Sell$0
CYCN▲ Buy$290K
CYCN▲ Buy$10K

We use analytics to understand how market-wall is used. No personal data is sold.